FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Fint of Type Respons	(3)								1			
1. Name and Address Bell John K	2. Issuer Name and Ticker or Trading Symbol DelMar Pharmaceuticals, Inc. [DMPI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
SUITE 720-999 W	(First) EST BROADW		3. Date of Earliest Transaction (Month/Day/Year) 04/29/2016						Officer (give title below)O	Other (specify be	ow)	
VANCOUVER, A	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)			2A. Deemed Execution Date, if any	Code		(A) or Disposed of (D)		of (D)	Reported Transaction(s)	Ownership of Indirec Form: Beneficia	7. Nature of Indirect Beneficial	
			(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	



Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Num	ber	6. Date Exerc	isable and	7. Title and		8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	ion	of		Expiration Da	te	Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)		Code		Derivat	tive	(Month/Day/	(ear)	Underlying		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Securities		Securities (Instr. 5)		Beneficially	Derivative	Ownership			
	Derivative					Acquir	quired		(Instr. 3 and 4)				~	(Instr. 4)	
	Security					(A) or						0	Direct (D)		
						Dispos	ed						1	or Indirect	
						of (D)							Transaction(s)	1 A A	
						(Instr. 3	3, 4,						(Instr. 4)	(Instr. 4)	
						and 5)									
											Amount				
								Date	Expiration		or				
								Exercisable	Date		Number				
				C 1	* *	(1)					of				
				Code	V	(A)	(D)				Shares				
Series B										C					See
Preferred	(1)	04/29/2016		<u>р(2)</u>		5,000		04/29/2016	<u>(3)</u>	Common Stock	50.000	\$8	5,000	Ι	Footnote
Stock				•		- ,				Stock	,		- ,		<u>(4)</u>
STOOR															~~~

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Bell John K SUITE 720-999 WEST BROADWAY VANCOUVER, A1 V5Z 1K5	Х						

Signatures

/s/ John K. Bell	05/02/2016	
Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Series B Preferred stock is convertible into such number of shares of common stock equal to the number of Preferred Shares to be converted, multiplied by the Stated Value of (1) \$8.00, divided by the Conversion Price in effect at the time of the conversion (the initial Conversion Price will be \$0.80, subject to adjustment in the event of stock splits, stock dividends, and similar transactions).
- (2) The Reporting Person purchased Series B Preferred Stock from the Company in a private placement on April 29, 2016 (the "Private Placement").
- The Series B Preferred Stock will automatically convert to common stock at the earlier of (a) the Company's lead product candidate, VAL-083, receiving Food and Drug (3) Administration or European Medicines Agency approval (provided that, at the time of such approval, the closing bid price of the common stock is at least \$2.00 (subject to adjustment for stock splits or stock dividends) or (b) five years from the final closing of the Private Placement.
- (4) The Series B Preferred Stock is held by Onbelay Capital Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.